3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Breast Neoplasms
103
Carcinoma, Renal Cell
70
Neoplasm Metastasis
48
Neoplasms
37
Neuroendocrine Tumors
33
Kidney Neoplasms
27
Recurrence
19
Tuberous Sclerosis
18
Carcinoma, Non-Small-Cell Lung
17
Prostatic Neoplasms
16
Triple Negative Breast Neoplasms
15
Lymphoma
15
Lymphoma, Mantle-Cell
14
Lymphoma, Large B-Cell, Diffuse
14
Head and Neck Neoplasms
14
Glioblastoma
14
Colorectal Neoplasms
13
Carcinoma, Hepatocellular
13
Stomach Neoplasms
12
Lung Neoplasms
12
Leukemia, Lymphocytic, Chronic, B-Cell
12
Hodgkin Disease
12
Brain Neoplasms
12
Sarcoma
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Pancreatic Neoplasms
11
Glioma
11
Waldenstrom Macroglobulinemia
10
Lymphoma, Follicular
10
Carcinoma, Neuroendocrine
10
Interventions
cemiplimab
3
Transdermal Patch
1
Sirolimus
1
Prednisone
1
Everolimus
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Cutaneous Squamous Cell Carcinoma
×
Everolimus
×
Clear all
NCT04339062
2025-04-23
CONTRAC
Dana-Farber Cancer Institute
Phase 1/2
Completed
12 enrolled
13 charts